Research programme: adult stem cell therapies - Caladrius Biosciences

Drug Profile

Research programme: adult stem cell therapies - Caladrius Biosciences

Latest Information Update: 04 Nov 2015

Price : $50

At a glance

  • Originator NeoStem
  • Developer Caladrius Biosciences; University of Louisville
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Acute radiation syndrome; Cardiovascular disorders; Eye disorders; Musculoskeletal disorders; Neurological disorders; Periodontal disorders; Wounds

Most Recent Events

  • 30 May 2013 Early research in Periodontal disorders in USA (Topical)
  • 25 Jun 2012 Early research in Acute radiation syndrome in USA (Parenteral)
  • 25 Jun 2012 NeoStem receives grant from National Institute of Allergy and Infectious Diseases for adult stem cell therapy development in Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top